ADMA Biologics, Inc. (ADMA) Q2 2016 Earnings Results

ADMA Biologics Misses on EPS, Stock Up 6.39%

ADMA Biologics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 6.39%, likely due to market optimism about future partnerships and operational strategies. Investors may be weighing the potential for recovery despite the current financial challenges.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.50	N/A	-33.33%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Overall, management expressed caution regarding the company's financial outlook. They acknowledged the need for continued focus on operational improvements.

Management highlighted ongoing challenges in achieving profitability.

They emphasized the importance of strategic partnerships moving forward.

ADMA Biologics Misses on EPS, Stock Up 6.39%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Up 6.39%

Key numbers

Management commentary